Insilico Medicine Analysis: $510M Raised
What is Insilico Medicine?
Insilico Medicine utilizes generative artificial intelligence to transform drug discovery and development, aiming to extend healthy longevity. The company focuses on reducing the time and cost associated with bringing medications to market, leveraging AI to identify new drug targets and molecules.
Location
111 Queen Anne Avenue North, Seattle, Washington 98019, United States
Employees
1-10
Founded
2003
Funding Status
Series E
Product Features & Capabilities
- PandaOmics
- PandaOmics Box
- Chemistry42
- Generative Biologics
- Science42: DORA
- inClinico
- PreciousGPT
Use Cases
Identify new drug targets using AI; Automate drug discovery processes; Generate biologics for therapeutic applications; Conduct in-depth chemical analysis; Model diseases for better treatment strategies
Other Considerations
Recognized as the most innovative biotechnology company in the world 2024; Engaged in over 20 drug discovery programs; Collaborates with major global enterprises; Holds multiple proprietary technologies in AI-driven drug discovery
See something that needs updating? Suggest edits to this profile.